Showing 1 - 2 results of 2 for search 'Matthew S. Block', query time: 0.01s Refine Results
  1. 1
    Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma

    Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma by Yuan Yao, Yiyi Yan, Vera J. Suman, Allan B. Dietz, Courtney L. Erskine, Anastasios Dimou, Svetomir N. Markovic, Svetomir N. Markovic, Robert R. McWilliams, Heather N. Montane, Matthew S. Block, Matthew S. Block

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial

    The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial by Matthew Stephen Block, James Hugo Armstrong Clubb, Johanna Mäenpää, Santeri Pakola, Dafne Carolina Alves Quixabeira, Tatiana Kudling, Elise Jirovec, Lyna Haybout, Mirte van der Heijden, Sanae Zahraoui, Susanna Grönberg-Vähä-Koskela, Sini Raatikainen, Victor Arias, Saru Basnet, Nea Ojala, Teijo Pellinen, Annabrita Hemmes, Katja Välimäki, Annukka Pasanen, Tuomo Alanko, Daniel Adamo, Susan Ramadan, Jorma Sormunen, Juha Kononen, Julia Wanda Cohen, Michael Jon Chisamore, John Goldfinch, Suvi Sorsa, Riikka Havunen, Claudia Kistler, Aino Kalervo, Víctor Cervera-Carrascon, João Manuel dos Santos, Akseli Hemminki

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: